Patent ID: 6696483
Filing Date: 2004-02-24
Classification: A61K

Abstract:
A pharmaceutical formulation for treating a patient in need of anti-angiogenic therapy comprising:a Golgi apparatus disturbing agent in an amount that is substantially noncytotoxic and effective to inhibit angiogenesis; a solvent; and a pharmaceutically acceptable carrier, wherein said Golgi apparatus disturbing agent is selected from the group consisting of brefeldin A, nocodazole, ilimaquinone, bafilamycin, okadaic acid, retinoic acid, and combinations thereof, and said solvent is selected from the group consisting of 1-butanol, 2-butanol, 3-methyl-1-butanol, 2-methyl-1-propanol, ethanol, propylene glycol, ethyl ether, ethyl formate, ethyl acetate, isobutyl acetate, isopropyl acetate, methylethyl ketone, dimethylacetamide, 1,1-dimethyloxymethane, 2,2-dimethyloxypropane, dimethylsulfoxide, and combinations thereof.